The abstract is read at the publisher; the summary is JClub's.
GLP-1 receptor agonist-based therapies and SGLT2 inhibitors are recommended for people with type 2 diabetes and MASLD/MASH, improving MASLD/MASH while also providing established cardiorenal benefits.
- Why it matters: MASLD spans from isolated steatosis to MASH, advanced fibrosis, and cirrhosis, and it is a leading global cause of chronic liver disease linked to major cardiometabolic conditions.
- What they did: This narrative review evaluates the efficacy of GLP-1 receptor agonists and SGLT2 inhibitors for MASLD/MASH, emphasizing metabolic benefits alongside other treatment approaches.
- The result: The review supports pharmacotherapy—especially GLP-1 and SGLT2 options—alongside lifestyle measures, implying these drugs may address shared cardiometabolic drivers of disease progression.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.